{"id":"ato-oxy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug works by improving oxygen delivery and utilization in hypoxic tissues, which stimulates angiogenesis, collagen deposition, and cellular proliferation necessary for wound healing. This mechanism is particularly relevant in chronic wounds where tissue hypoxia impairs the natural healing cascade.","oneSentence":"Ato-oxy is an oxygen-based therapeutic that enhances tissue oxygenation to promote wound healing and tissue repair.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:19:30.426Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic wounds and diabetic foot ulcers"}]},"trialDetails":[{"nctId":"NCT07280468","phase":"PHASE4","title":"Endotype DIrected Treatment for OSA in Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-01","conditions":"Obstructive Sleep Apnea (OSA), Down Syndrome","enrollment":200},{"nctId":"NCT04115878","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2020-10-21","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":22},{"nctId":"NCT05933603","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-09-29","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["atomoxetine and oxybutynin"],"phase":"marketed","status":"active","brandName":"ato-oxy","genericName":"ato-oxy","companyName":"University of Arizona","companyId":"university-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ato-oxy is an oxygen-based therapeutic that enhances tissue oxygenation to promote wound healing and tissue repair. Used for Chronic wounds and diabetic foot ulcers.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}